Lifeboat Foundation

Read how Congress is pressing the DEA to reclassify marijuana from a Schedule I drug to Schedule III.

Marijuana is currently classified as a Schedule I drug, meaning these are “drugs with no currently accepted medical use and a high potential for abuse.” However, a team of 21 bipartisan congressional leaders from both the Senate and House of Representatives hopes to change that as they recently sent a letter to the United States Drug Enforcement Administration (DEA) pushing them to “promptly remove marijuana from Schedule I of the Controlled Substances Act (CSA)”, noting that almost eight months had passed “since the Department of Health and Human Services (HHS) recommended rescheduling marijuana to Schedule III — and 18 months since President Biden directed HHS and the Department of Justice (DOJ) to begin the process of reviewing marijuana’s scheduling.”

Examples of other Schedule I drugs include heroin, lysergic acid diethylamide (LSD), marijuana (cannabis), 3,4-methylenedioxymethamphetamine (ecstasy), methaqualone, and peyote, while Schedule III drugs include Tylenol, ketamine, anabolic steroids, and testosterone. Additionally, the penalties between Schedule I and Schedule III drugs also demonstrate stark contrasts, as well.

Continue reading “Bipartisan Effort Demands DEA Action on Marijuana Scheduling” »

02:15 Consciousness as an illusion10:02 How would a belief look in the brain?23:07 Two kinds of dualism29:49 What if you and I see blue differently?38:34 Is…

A newly developed nanomaterial that mimics the behavior of proteins could be an effective tool for treating Alzheimer’s and other neurodegenerative diseases. The nanomaterial alters the interaction between two key proteins in brain cells—with a potentially powerful therapeutic effect.

The innovative findings, recently published in the journal Advanced Materials, were made possible thanks to a collaboration between University of Wisconsin–Madison scientists and nanomaterial engineers at Northwestern University.

The work centers around altering the interaction between two proteins that are believed to be involved in setting the stage for diseases like Alzheimer’s, Parkinson’s and amyotrophic lateral sclerosis, or ALS.

Cognitive decline and dementia already affect more than 55 million people worldwide. This number is projected to skyrocket over the next few decades as the global population ages.

There are certain risk factors of cognitive decline and dementia that we cannot change – such as having a genetic predisposition to these conditions. But other risk factors we may have more power over – with research showing certain modifiable lifestyle habits, such as smoking, obesity and lack of exercise, are all linked to higher risk of dementia.

What role nutrition plays in preventing cognitive decline and dementia has also been the focus of scientific research for quite some time.

Using electromagnetic fields or implanted medical devices to stimulate the brain can have benefits, but also carries risks. Computer simulations that reflect the unique complexity of each patient can help predict and solve problems before they arise.

Computers work in digits — 0s and 1s to be exact. Their calculations are digital; their processes are digital; even their memories are digital. All of which requires extraordinary power resources. As we look to the next evolution of computing and developing neuromorphic or “brain-like” computing, those power requirements are unfeasible.

To advance neuromorphic computing, some researchers are looking at analog improvements. In other words, not just advancing software, but advancing hardware too. Research from the University of California San Diego and UC Riverside shows a promising new way to store and transmit information using disordered superconducting loops.

The team’s research, which appears in the Proceedings of the National Academy of Sciences, offers the ability of superconducting loops to demonstrate associative memory, which, in humans, allows the brain to remember the relationship between two unrelated items.

Post-mitotic neurons in the brain that re-enter the cell cycle quickly succumb to senescence, and this re-entry is more common in Alzheimer’s disease, according to a new study published April 9 in the open-access journal PLOS Biology by Kim Hai-Man Chow and colleagues at the Chinese University of Hong Kong.

The phenomenon may provide an opportunity to learn more about the neurodegeneration process, and the technique used to make this discovery is readily applicable to other inquiries about unique populations of cells in the brain.

Most neurons in the brain are post-mitotic, meaning they have ceased to divide. For many years, it had been assumed that this post-mitotic state was permanent. Recent discoveries have shown that a small proportion of neurons re-enter the cell cycle, but little is known about their fate after they do.

The constant ebb and flow of hormones that guide the menstrual cycle don’t just affect reproductive anatomy. They also reshape the brain, and a study has given us insight into how this happens.

Led by neuroscientists Elizabeth Rizor and Viktoriya Babenko of the University of California Santa Barbara, a team of researchers tracked 30 women who menstruate over their cycles, documenting in detail the structural changes that take place in the brain as hormonal profiles fluctuate.

The results, which are yet to be peer-reviewed but can be found on preprint server bioRxiv, suggest that structural changes in the brain during menstruation may not be limited to those regions associated with the menstrual cycle.

Rice University engineers have developed the smallest implantable brain stimulator demonstrated in a human patient. Thanks to pioneering magnetoelectric power transfer technology, the pea-sized device developed in the Rice lab of Jacob Robinson in collaboration with Motif Neurotech and clinicians Dr. Sameer Sheth and Dr. Sunil Sheth can be powered wirelessly via an external transmitter and used to stimulate the brain through the dura ⎯ the protective membrane attached to the bottom of the skull.

The device, known as the Digitally programmable Over-brain Therapeutic (DOT), could revolutionize treatment for drug-resistant depression and other psychiatric or neurological disorders by providing a therapeutic alternative that offers greater patient autonomy and accessibility than current neurostimulation-based therapies and is less invasive than other brain-computer interfaces (BCIs).